You just read:

VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy

News provided by

VM BioPharma

27 Jun, 2016, 08:00 ET